A Multicenter, Open-label, Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced Human Epidermal Growth Factor Receptor 2 Positive(HER2+) Solid Tumors

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 29 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AB-201-Artiva Biotherapeutics (Primary) ; Cyclophosphamide; Fludarabine
Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; Oesophageal cancer; Solid tumours
Focus Adverse reactions
Sponsors GC Cell

Most Recent Events

24 Jan 2025 Status changed from not yet recruiting to withdrawn prior to enrolment. (Reason the study was stopped: Determined that enrollment would be limited due to the change in care setting).
21 Aug 2024 Planned initiation date changed from 31 Aug 2024 to 31 Oct 2024.
05 Apr 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight